Journal
CELLS
Volume 11, Issue 19, Pages -Publisher
MDPI
DOI: 10.3390/cells11192974
Keywords
PXR; pregnane X receptor; allosteric site; AF-2 site; BF-3 site; PAM-antagonist; CAR
Categories
Funding
- Technology Agency of the Czech Republic (The Council of the National Centre of Competence-Personalized Medicine-Diagnostics and Therapy) [TN01000013]
- Czech Scientific Agency [22-05167S]
- 4EU+ (4EU+ European University Alliance)
- EU [825762]
- [SVV 260 549]
Ask authors/readers for more resources
This article summarizes the allosteric modulation of PXR and the exploration of novel allosteric sites. The identified allosteric sites of PXR provide new insights into the development of safe and efficient allosteric modulators, which may become promising targets for treating chronic metabolic diseases and some cancers.
The pregnane X receptor (PXR, NR1I2) is a xenobiotic-activated transcription factor with high levels of expression in the liver. It not only plays a key role in drug metabolism and elimination, but also promotes tumor growth, drug resistance, and metabolic diseases. It has been proposed as a therapeutic target for type II diabetes, metabolic syndrome, and inflammatory bowel disease, and PXR antagonists have recently been considered as a therapy for colon cancer. There are currently no PXR antagonists that can be used in a clinical setting. Nevertheless, due to the large and complex ligand-binding pocket (LBP) of the PXR, it is challenging to discover PXR antagonists at the orthosteric site. Alternative ligand binding sites of the PXR have also been proposed and are currently being studied. Recently, the AF-2 allosteric binding site of the PXR has been identified, with several compounds modulating the site discovered. Herein, we aimed to summarize our current knowledge of allosteric modulation of the PXR as well as our attempt to unlock novel allosteric sites. We describe the novel binding function 3 (BF-3) site of PXR, which is also common for other nuclear receptors. In addition, we also mention a novel allosteric site III based on in silico prediction. The identified allosteric sites of the PXR provide new insights into the development of safe and efficient allosteric modulators of the PXR receptor. We therefore propose that novel PXR allosteric sites might be promising targets for treating chronic metabolic diseases and some cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available